Skip to main content
PMC home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2007 Feb 14;29(11):482–488. doi: 10.1002/clc.4960291103

Nitric oxide synthase inhibitors in post‐myocardial infarction cardiogenic shock—an update

Edo Kaluski 1,✉, Alberto Hendler 1, Alex Blatt 1, Nir Uriel 1
PMCID: PMC6654158  PMID: 17133844

Abstract

Cardiogenic shock (CS) in acute myocardial infarction, after successful coronary angioplasty, still carries a case fatality rate of 50%. These patients succumb to a systemic metabolic storm, superimposed on extensive myocardial necrosis and stunning. Nitric oxide (NO) overproduction contributes to the pathophysiology of this morbid state. Current data regarding the physiologic effects of NO and nitric oxide synthase (NOS) inhibitors on the cardiovascular system are reviewed. Clinical trials assessing the safety and efficacy of NOS inhibitors in CS are summarized.

Keywords: nitric oxide, nitric oxide synthase inhibitors, cardiogenic shock, NG‐monomethyl‐L arginine acetate, ST‐elevation myocardial infarction

Full Text

The Full Text of this article is available as a PDF (132.5 KB).

References

  • 1. Lundbeg JO, Weitzberg E: No generation from nitrite and its role in vascular control. Arterioscler Thromb VaSc Biol 2005; 25: 915–922 [DOI] [PubMed] [Google Scholar]
  • 2. Lundberg JO: Nitric oxide metabolites and cardiovascular disease. J Am Coll Cardiol 2006; 47: 580–581 [DOI] [PubMed] [Google Scholar]
  • 3. Heiss C, Lauer T, Dejam A: Plasma nitroso compounds are decreased in patients with endothelial dysfunction. J Am Coll Cardiol 2006; 47: 573–579 [DOI] [PubMed] [Google Scholar]
  • 4. de Werra I, Jaccard C, Corradin SB, Chiolero R, Yersin B, Gallati H, Assicot M, Bohuon C, Baumgartner JD, Glauser MP, Heumann D: Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptors, and procalcitonin concentrations: Comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia. Crit Care Med 1997; 25 (4): 607–613 [DOI] [PubMed] [Google Scholar]
  • 5. Katayama T, Nakashima H, Furudono S, Honda Y, Suzuki S, Yano K: Evaluation of neurohumoral activation (adrenomedullin, BNP, catecholamines, etc.) in patients with acute myocardial infarction. Intern Med 2004; 43 (11): 1015–1022 [DOI] [PubMed] [Google Scholar]
  • 6. Vantrimpont P, Rouleau JL, Ciampi A, Harel F, de Champlain J, Bichet D, Moyé LA, Pfeffer M: Two‐year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study. Eur Heart J 1998; 19 (10): 1552–1563 [DOI] [PubMed] [Google Scholar]
  • 7. Katayama T, Nakashima H, Takagi C, Honda Y, Suzuki S, Yano K: Predictors of mortality in patients with acute myocardial infarction and cardiogenic shock. Circ J 2005; 69 (1): 83–88 [DOI] [PubMed] [Google Scholar]
  • 8. Hochman JS: Cardiogenic shock complicating acute myocardial infarction: Expanding the paradigm. Circulation 2003; 107 (24): 2998–3002 [DOI] [PubMed] [Google Scholar]
  • 9. Depre C, Gaussin V, Ponchaut S, Fischer Y, Vanoverschelde JL, Hue L: Inhibition of myocardial glucose uptake by cGMP. Am J Physiol 1998; 274: H1443–449 [DOI] [PubMed] [Google Scholar]
  • 10. Tada H, Thompson CI, Recchia FA, Loke KE, Ochoa M, Smith CJ, Shesely EG, Kaley G, Hintze TH: Myocardial glucose uptake is regulated by nitric oxide via endothelial nitric oxide synthase in Langendorff mouse heart. Circ Res 2000; 86 (3): 270–274 [DOI] [PubMed] [Google Scholar]
  • 11. Zhang J, Gong G, Ye Y, Guo T, Mansoor A, Hu Q, Ochiai K, Liu J, Wang X, Cheng Y, Iverson N, Lee J, From AH, Ugurbil K, Bache R J: Nitric oxide regulation of myocardial O2 consumption and HEP metabolism. Am J Physiol Heart Circ Physiol 2005; 288 (1): H310–316 [DOI] [PubMed] [Google Scholar]
  • 12. Tatsumi T, Matoba S, Kawahara A, Keira N, Shiraishi J, Akashi K, Kobara M, Tanaka T, Katamura M, Nakagawa C, Ohta B, Shirayama T, Takeda K, Asayama J, Fliss H, Nakagawa M: Cytokine‐induced nitric oxide production inhibits mitochondrial energy production and impairs contractile function in rat cardiac myocytes. J Am Coll Cardiol 2000; 35 (5): 1338–1346 [DOI] [PubMed] [Google Scholar]
  • 13. Traverse JH, Chen Y, Hou M, Bache RJ: Inhibition of NO production increases myocardial blood flow and oxygen consumption in congestive heart failure. Am J Physiol Heart Circ Physiol 2002; 282 (6): H2278–H2283 [DOI] [PubMed] [Google Scholar]
  • 14. Chen Y, Traverse JH, Du R, Hou M, Bache RJ: Nitric oxide modulates myocardial oxygen consumption in the failing heart. Circulation 2002; 106 (2): 273–279 [DOI] [PubMed] [Google Scholar]
  • 15. Martin C, Schulz R, Post H, Gres P, Heusch G: Effect of NO synthase inhibition on myocardial metabolism during moderate ischemia. Am J Physiol Heart Circ Physiol 2003; 284 (6): H2320–H2324 [DOI] [PubMed] [Google Scholar]
  • 16. Ziolo MT, Maier LS, Piacentino V III, Bossuyt J, Houser SR, Bers DM: Myocyte nitric oxide synthase 2 contributes to blunted beta‐adrenergic response in failing human hearts by decreasing Ca2+ transients. Circulation 2004; 109 (15): 1886–1891 [DOI] [PubMed] [Google Scholar]
  • 17. Gealekman O, Abassi Z, Rubinstein I, Winaver J, Binah O: Role of myocardial inducible nitric oxide synthase in contractile dysfunction and beta‐adrenergic hyporesponsiveness in rats with experimental volume‐overload heart failure. Circulation 2002; 105 (2): 236–243 [DOI] [PubMed] [Google Scholar]
  • 18. Drexler H, Kastner S, Strobel A, Studer R, Brodde OE, Hasenfuss G: Expression, activity and functional significance of inducible nitric oxide synthase in the failing human heart. J Am Coll Cardiol 1998; 32 (4): 955–963 [DOI] [PubMed] [Google Scholar]
  • 19. Barouch LA, Harrison RW, Skaf MW, Rosas GO, Cappola TP, Kobeissi ZA, Hobai IA, Lemmon CA, Burnett AL, O'Rourke B, Rodriguez ER, Huang PL, Lima JA, Berkowitz DE, Hare JM: Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nature 2002; 416 (6878): 337–339 [DOI] [PubMed] [Google Scholar]
  • 20. Kaluski E, Milo O, Uriel N, Vered Z, Cotter G: Nitric oxide synthase inhibitors in refractory cardiogenic shock due to myocardial infarction after percutaneous coronary interventions. Heart Drug 2005; 5: 5161–5167 [Google Scholar]
  • 21. Hare JM: Spatial confinement of isoforms of cardiac nitric‐oxide synthase: Unraveling the complexities of nitric oxide's cardiobiology. Lancet 2004; 363 (9418): 1338–1339 [DOI] [PubMed] [Google Scholar]
  • 22. Carnendran L, Abboud R, Sleeper LA, Gurunathan R, Webb JG, Menon V, Dzavik V, Cocke T, Hochman JS: Trends in cardiogenic shock: Report from the SHOCK Study. The Should we emergently revascularize Occluded Coronaries for cardiogenic shock? Eur Heart J 2001; 22 (6): 472–478 [DOI] [PubMed] [Google Scholar]
  • 23. Jacobs AK, Leopold JA, Bates E, Mendes LA, Sleeper LA, White H, Davidoff R, Boland J, Modur S, Forman R, Hochman JS: Cardiogenic shock caused by right ventricular infarction: A report from the SHOCK registry. J Am Coll Cardiol 2003; 16; 41 (8): 1273–1279 [DOI] [PubMed] [Google Scholar]
  • 24. Hochman JS, Buller CE, Sleeper LA, Boland J, Dzavik V, Sanborn TA, Godfrey E, White HD, Lim J, LeJemtel T: Cardiogenic shock complicating acute myocardial infarction—etiologies, management and outcome: A report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol 2000; 36 (3 suppl A): 1063–1070 [DOI] [PubMed] [Google Scholar]
  • 25. Menon V, Hochman JS, Stebbins A, Pfisterer M, Col J, Anderson RD, Hasdai D, Holmes DR, Bates ER, Topol EJ, Califf RM, Ohman EM: Lack of progress in cardiogenic shock: Lessons from the GUSTO trials. Eur Heart J 2000; 21 (23): 1928–1936 [DOI] [PubMed] [Google Scholar]
  • 26. Menon V, Fincke R: Cardiogenic shock: A summary of the randomized SHOCK trial. Congest Heart Fail 2003; 9 (1): 35–39 [DOI] [PubMed] [Google Scholar]
  • 27. Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, Buller CE, Jacobs AK, Slater JN, Col J, McKinlay SM, LeJemtel TH, For the SHOCK Investigators : Early revascularization in acute myocardial infarction complicated by cardiogenic shock. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med 1999; 341 (9): 625–634 [DOI] [PubMed] [Google Scholar]
  • 28. Dzavik V, Sleeper LA, Cocke TP, Moscucci M, Saucedo J, Hosat S, Jiang X, Slater J, LeJemtel T, Hochman JS, for the SHOCK Investigators : Early revascularization is associated with improved survival in elderly patients with acute myocardial infarction complicated by cardiogenic shock: A report from the SHOCK Trial Registry. Eur Heart J 2003; 24 (9): 828–837 [DOI] [PubMed] [Google Scholar]
  • 29. Webb JG, Lowe AM, Sanborn TA, White HD, Sleeper LA, Carere RG, Buller CE, Wong SC, Boland J, Dzavik V, Porway M, Pate G, Bergman G, Hochman JS, for the SHOCK Investigators : Percutaneous coronary intervention for cardiogenic shock in the SHOCK trial. J Am Coll Cardiol 2003; 42 (8): 1380–1386 [DOI] [PubMed] [Google Scholar]
  • 30. Wong SC, Sanborn T, Sleeper LA, Webb JG, Pilchik R, Hart D, Mejnartowicz S, Antonelli TA, Lange R, French JK, Bergman G, LeJemtel T, Hochman JS: Angiographic findings and clinical correlates in patients with cardiogenic shock complicating acute myocardial infarction: A report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol 2000; 36 (3 suppl A): 1077–1083 [DOI] [PubMed] [Google Scholar]
  • 31. Cotter G, Moshkovitz Y, Kaluski E, Milo O, Nobikov Y, Schneeweiss A, Krakover R, Vered Z: The role of cardiac power and systemic vascular resistance in the pathophysiology and diagnosis of patients with acute congestive heart failure. Eur J Heart Fail 2003; 5 (4): 443–451 [DOI] [PubMed] [Google Scholar]
  • 32. Fincke R, Hochman JS, Lowe AM, Menon V, Slater JN, Webb JG, LeJemtel TH, Cotter G, for the SHOCK Investigators : Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: A report from the SHOCK trial registry. J Am Coll Cardiol 2004; 44 (2): 340–348 [DOI] [PubMed] [Google Scholar]
  • 33. Zeymer U, Vogt A, Zahn R, Weber MA, Tebbe U, Gottwik M, Bonzel T, Senges J, Neuhaus KL, for the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte (ALKK): Predictors of in‐hospital mortality in 1,333 patients with acute myocardial infarction complicated by cardiogenic shock treated with primary percutaneous coronary intervention (PCI): Results of the primary PCI registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte (ALKK). Eur Heart J 2004; 25 (4): 322–328 [DOI] [PubMed] [Google Scholar]
  • 34. Picard MH, Davidoff R, Sleeper LA, Mendes LA, Thompson CR, Dzavik V, Steingart R, Gin K, White HD, Hochman JS: SHOCK Trial: SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK. Echocardiographic predictors of survival and response to early revascularization in cardiogenic shock. Circulation 2003; 107 (2): 279–284 [DOI] [PubMed] [Google Scholar]
  • 35. Hochman JS, Sleeper LA, White HD, Dzavik V, Wong SC, Menon V, Webb JG, Steingart R, Picard MH, Menegus MA, Boland J, Sanborn T, Buller CE, Modur S, Forman R, Desvigne‐Nickens P, Jacobs AK, Slater JN, LeJemtel TH, for the SHOCK Investigators : Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. One‐year survival following early revascularization for cardiogenic shock. J Am Med Assoc 2001; 285 (2): 190–192 [DOI] [PubMed] [Google Scholar]
  • 36. Cotter G, Kaluski E, Blatt A, Milovanov O, Moshkovitz Y, Zaidenstein R, Salah A, Alon D, Michovitz Y, Metzger M, Vered Z, Golik A: L‐NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock. Circulation 2000; 101 (12): 1358–1361 [DOI] [PubMed] [Google Scholar]
  • 37. Investigator Brochure‐August 19, 2003. LNMMA Injection (ANO‐1020), Arginox Pharmaceutical, Inc. [Google Scholar]
  • 38. Cotter G, Kaluski E, Milo O, Blatt A, Salah A, Hendler A, Krakover R, Golick A, Vered Z: LINCS: L‐NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock: A prospective randomized study. Eur Heart J 2003; 24 (14): 1287–1295 [DOI] [PubMed] [Google Scholar]
  • 39. Dzavik V, Cotter G., Farkouh ME, Ramanathan K, Reynolds HR, Baran D, Cantor W, Menon V, Kaluski E, Prondzinsky R, Stebbins A, Hochman JS, on behalf of the SHOCK‐2 Investigators : Effect of nitric oxide synthase inhibition on hemodynamics and outcome of patients with acute myocardial infarction complicated by cardiogenic shock: A Phase 2 dose‐ranging study. American Heart Association Scientific Sessions, November 8, 2004.
  • 40. A study of safety and efficacy of nitric oxide reduction in patients with cardiogenic shock after heart attack (NCT001 12281) posted on the internet at http://www.clinicaltrials.gov/ct/

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES